Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2022 and Fiscal Year Ending March 31, 2022
July 29, 2022 at 07:00 am
Share
Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the six months ending September 30, 2022 and fiscal year ending March 31, 2022. For the six months ending, the company expected to report revenue of JPY 10,570 million and operating profit of JPY 2,510 million. the expected profit attributable to owners of parent is JPY 3,310 million and profit per share is JPY 79.50.
For the fiscal year ending, the company expected to report revenue of JPY 22,830 million and operating profit of JPY 5,210 million. the expected profit attributable to owners of parent is JPY 5,590 million and profit per share is JPY 134.27.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2022 and Fiscal Year Ending March 31, 2022
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 
